A Phase 1b Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Patients With Relapsed or Refractory Multiple Myeloma (MM)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 14 Dec 2017 Planned End Date changed from 31 Jan 2018 to 31 May 2018.
- 14 Dec 2017 Planned primary completion date changed from 6 Nov 2017 to 31 May 2018.
- 16 Oct 2017 Planned End Date changed from 6 Nov 2017 to 31 Jan 2018.